(D-Pro2,D-Trp7·9)-Substance P

Research use only, not for human use.

[D-Pro2,D-Trp7,9] Substance P, a Substance P analogue, is a weak agonist and a potent, specific, competitive Substance P antagonist.

[D-Pro2,D-Trp7,9] Substance P, a Substance P analogue, is a weak agonist and a potent, specific, competitive Substance P antagonist.

[D-Pro2,D-Trp7,9] Substance P decreases proliferation only in a few cell lines, and only in the highest concentration (100 μM). [D-Pro2,D-Trp7,9] Substance P displays a significantly weaker antiproliferative action than Aprepitant on cancer or normal cell lines.

[D-Pro2,D-Trp7,9] Substance P (0-30 nmol, Intravitreal injection) greatly reduces not only the effects of exogenous Substance P but also the inflammatory response to trauma to the eye.[D-Pro2,D-Trp7,9] Substance P specifically antagonizes the contractile effects of Substance P on the guinea-pig isolated taenia coli.Animal Model:Adult pigmented rabbits (1.5-3 kg) Dosage:0.03, 0.3, 3, and 30 nmol Administration:Intravitreal injection or topical application onto the eye, 60 μL Result:Reduced the inflammatory response to Substance P. Dependently reduced the inflammatory response to infrared irradiation. In itself, intravitreal injection of low doses of [D-Pro2, D-Trp7'9]SP had no effects on the eye.

———

Others

Other Targets

———

———

———

80434-86-2

1515.86

C74H106N20O13S

>98% (HPLC)

———

———

——

(-20℃)

With Ice Pack

≥ 2 years